PHP
RCUS icon

Parkman Healthcare Partners’s Arcus Biosciences RCUS Stock Holding History

Parkman Healthcare Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.3M Sell
919,266
-288,008
-24% -$7.12M 2.9% 6
2026
Q1 		$26.1M Buy
1,207,274
+238,672
+25% +$5.15M 2.69% 10
2025
Q4 		$23.1M Buy
968,602
+315,922
+48% +$6.45M 2.2% 14
2025
Q3 		$8.88M Buy
652,680
+53,070
+9% +$552K 0.93% 40
2025
Q2 		$4.88M Sell
599,610
-616,019
-51% -$5.26M 0.56% 62
2025
Q1 		$9.54M Sell
1,215,629
-58,160
-5% -$674K 1.13% 32
2024
Q4 		$19M Buy
1,273,789
+248,035
+24% +$4.05M 2.53% 13
2024
Q3 		$15.7M Buy
1,025,754
+610,219
+147% +$9.62M 2% 14
2024
Q2 		$6.33M Buy
415,535
+155,615
+60% +$2.51M 0.85% 42
2024
Q1 		$4.91M Buy
259,920
+12,256
+5% +$212K 0.6% 53
2023
Q4 		$4.73M Buy
247,664
+42,555
+21% +$680K 0.67% 48
2023
Q3 		$3.68M Buy
205,109
+85,060
+71% +$1.71M 0.67% 43
2023
Q2 		$2.44M Buy
120,049
+17,062
+17% +$325K 0.42% 67
2023
Q1 		$1.88M Buy
102,987
+15,527
+18% +$297K 0.41% 59
2022
Q4 		$1.81M Sell
87,460
-50,434
-37% -$1.39M 0.48% 59
2022
Q3 		$3.61M Sell
137,894
-33,320
-19% -$881K 1.03% 36
2022
Q2 		$4.34M Buy
171,214
+3,893
+2% +$95.3K 1.6% 22
2022
Q1 		$5.28M Buy
167,321
+50,222
+43% +$1.68M 1.55% 24
2021
Q4 		$4.74M Sell
117,099
-119,538
-51% -$4.64M 1.05% 30
2021
Q3 		$8.25M Sell
236,637
-10,000
-4% -$311K 2.09% 17
2021
Q2 		$6.77M Sell
246,637
-69,245
-22% -$1.98M 1.48% 23
2021
Q1 		$8.87M Buy
315,882
+84,124
+36% +$2.93M 2.06% 14
2020
Q4 		$6.02M Sell
231,758
-3,280
-1% -$79.4K 1.54% 25
2020
Q3 		$4.03M Buy
235,038
+75,038
+47% +$1.68M 1.07% 39
2020
Q2 		$3.96M Buy
+160,000
New +$4.32M 1.12% 34

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Parkman Healthcare Partners's RCUS Position: Q2 2026 in Review

Parkman Healthcare Partners reduced its Arcus Biosciences (RCUS) stake by 24% in Q2 2026, selling an estimated $7.12M and leaving 919,266 shares worth $28.3M. The position accounts for 2.9% of the portfolio, ranked #6.

Parkman Healthcare Partners first reported a position in RCUS in Q2 2020 and has held it in 25 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Parkman Healthcare Partners held 919,266 shares of Arcus Biosciences worth $28.3M as of Q2 2026.
  • Parkman Healthcare Partners sold 288,008 Arcus Biosciences shares in Q2 2026, an estimated $7.12M.
  • Arcus Biosciences made up 2.9% of Parkman Healthcare Partners's portfolio in Q2 2026, its #6 holding.
  • Parkman Healthcare Partners first reported a position in Arcus Biosciences in Q2 2020 and has held it in 25 quarters since.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.